Clinical Implications of Inflammation in Acute Myeloid Leukemia

Christian Récher*

Service d’Hémato-oncologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France

Recent advances in the description of the tumor microenvironment of acute myeloid leukemia, including the comprehensive analysis of the leukemic stem cell niche and clonal evolution, indicate that inflammation may play a major role in many aspects of acute myeloid leukemia (AML) such as disease progression, chemoresistance, and myelosuppression. Studies on the mechanisms of resistance to chemotherapy or tyrosine kinase inhibitors along with high-throughput drug screening have underpinned the potential role of glucocorticoids in this disease classically described as steroid-resistant in contrast to acute lymphoblastic leukemia. Moreover, some mutated oncogenes such as RUNX1, NPM1, or SRSF2 transcriptionally modulate cell state in a manner that primes leukemic cells for glucocorticoid sensitivity. In clinical practice, inflammatory markers such as serum ferritin or IL-6 have a strong prognostic impact and may directly affect disease progression, whereas interesting preliminary data suggested that dexamethasone may improve the outcome for AML patients with a high white blood cell count, which paves the way to develop prospective clinical trials that evaluate the role of glucocorticoids in AML.

Keywords: acute myeloid leukemia, inflammation, glucocorticoids, dexamethasone, RUNX1, FLT3, leukemic stem cells, chemoresistance

INTRODUCTION

Acute myeloid leukemia (AML) is a myeloid malignancy induced by the oncogenic transformation of hematopoietic progenitors in the bone marrow leading to the destruction of blood tissue responsible for acute pancytopenia, severe bleeding, and infection (1). For over 40 years, intensive treatment of AML has been based on a combination of cytarabine and an anthracycline as induction chemotherapy, followed by intermediate to high-dose cytarabine consolidation and possibly allogeneic stem cell transplantation aimed at curing the disease. On the other hand, older patients or those deemed unfit for high intensity treatment received low-dose cytarabine or more recently, hypomethylating agents, both of which induce few complete responses and no hope for cure (2). While it used to be commonly acknowledged that there was no progress in the treatment of AML compared to other hematological malignancies, recently there has been a major effort to understand the disease and to develop novel promising drugs that specifically target recurrent gene mutations, apoptotic pathways, and cell surface antigens or by reformulating classical cytotoxic agents. Midostaurin, gemtuzumab ozogamycin, glasdegib, venetoclax, ivosidenib, enasidenib, gilteritinib and CPX-351 were approved by the Food and Drug Administration for AML patients.
in less than 2 years between 2017 and 2018, which brings hope for this highly fatal disease and many opportunities for clinical research (3, 4).

In the era of next-generation sequencing, considerable progress has been made in understanding leukemogenesis, the genetic diversity of AML, gene-gene interactions, clonal evolution, and the assessment of treatment responses (5–11). Several functional categories of recurrent gene mutations that affect transcription factors, cell signalization, nucleophosmin, epigenetics, DNA methylation, and RNA splicing or the cohesin complex interact to produce the main hallmarks of cancer and transform hematopoietic progenitors into AML cells. While much attention has been focused on these molecular alterations in recent years, another cancer hallmark, tumor-promoting inflammation, has on the contrary, received little attention in the field of AML (12). However, clinical findings, previous data as well as recent advances in the description of the tumor microenvironment of AML, including a comprehensive analysis of the leukemic stem cell niche, indicate that inflammation may play a role in many aspects of AML such as disease progression, chemoresistance, and myelosuppression or leukostasis syndrome (13). In this review, we highlight emerging data on the clinical and preclinical impact of inflammation in AML and the first attempts to modulate this phenomenon with anti-inflammatory drugs such as dexamethasone.

CLINICAL PRACTICE

The Inflammatory Response in AML Patients Treated With Intensive Chemotherapy

In routine clinical practice it is not uncommon to observe fever induced by chemotherapy in AML patients (14). The so-called cytarabine syndrome, which includes fever, myalgia, bone pain, maculopapular rash, conjunctivitis, malaise, and occasionally pericarditis, has long been described (15). Steroids can help to prevent or treat this syndrome. Fever is induced by endogenous pyrogens such as the interleukins IL-1α, IL-1β, IL-6, and TNF-α involved in the inflammatory response. It has been shown that high-dose cytarabine treatment induces a release of TNF-alpha followed by the sequential release of other proinflammatory cytokines (16, 17). This is consistent with the findings in a series of unselected AML patients treated by intensive induction chemotherapy with 3–5 days of anthracyclines and 7 days of cytarabine where inflammatory markers including serum ferritin and CRP levels were significantly increased at day 8 (as much as a 3.5-fold increase compared to baseline) (18). These data indicate that intensive chemotherapy, whether with 3 + 7 induction or high-dose cytarabine consolidation, often induces an inflammatory response in AML patients. The physiopathological consequences of this response remain unclear. In this context, inflammation may be further aggravated by infection during chemotherapy-induced myelosuppression or hyperinflammatory states such as hyperferritinemic syndrome or hemophagocytic lymphohistiocytosis, an immune dysregulation characterized by severe organ damage induced by an exacerbated inflammatory response and uncontrolled T-cell and macrophage activation. Secondary hemophagocytic lymphohistiocytosis typically occurs in association with severe infections or malignancies (19, 20). In a large series of AML patients treated by intensive chemotherapy, ~10% of the patients were noted to have fever, very high serum ferritin levels and bone marrow hemophagocytosis accompanied by hepatomegaly, pulmonary or neurological symptoms, liver abnormalities, a lower platelet count, higher levels of C-reactive protein and prolonged pancytopenia. The possibility of an infectious etiology that functions as a trigger for hyperinflammation, including bacterial, fungal, or *Herpesviridae* infections, was documented in 75% of the cases. In this study, hemophagocytic lymphohistiocytosis was associated with poor overall survival, which suggests that inflammation may impact prognosis in AML patients (21). With the current SARS-CoV-2 pandemic, hyperferritinemic syndromes and the pathogenic role of ferritin in critically ill patients are receiving considerable attention in terms of prognosis, clinical management, and therapeutic intervention (22–24).

Serum Ferritin in AML: More Than a Prognostic Marker

The role of cytokines and inflammatory pathways in AML was recently reviewed in other studies (13, 25, 26). Special attention was paid to IL-1 and IL-6 which have been associated with a poor prognosis, chemoresistance, and myelosuppression in AML (27–30). Here, we focus on recent data regarding the impact of ferritin in AML. In fact, independently of hyperinflammatory syndromes, it has also been observed that most AML patients have elevated serum ferritin levels at diagnosis, even younger patients with de novo AML who in general have had no red blood cell transfusion at the time of diagnosis (18, 31). This suggests that the increase in ferritin is most likely due to an underlying inflammatory condition rather than iron overload or liver damage. A recent study of a cohort of 525 AML patients treated with intensive chemotherapy showed that a higher ferritin level was significantly associated with age, higher CRP levels, leukocytosis, FAB M4/M5 subtypes, NPM1, and FLT3-ITD mutations (18). More importantly, serum ferritin was a risk factor for a poor response to treatment, early death, the incidence of relapse and survival endpoints independently of cytogenetics, molecular alterations or allogeneic stem cell transplantation. The median OS was 41.0 months in patients with serum ferritin ≤900 µg/l (3-fold the UNL) compared to 14.4 months in patients with >900 µg/l. Other studies have reported a poor prognostic impact of ferritin in AML patients (31–33). It is also noteworthy that in most cases CRP levels are usually elevated at diagnosis, but CRP had no prognostic impact in patients treated with intensive chemotherapy when serum ferritin was in a multivariate model (31, 33).

The fact that there is a significant association between serum ferritin levels and a poorer response to induction chemotherapy as well as a higher incidence of relapse would suggest that in addition to this statistical correlation ferritin also plays a role in chemoresistance. Overexpression of H-ferritin contributes to
lymphomagenesis and has been involved in resistance to chemotherapy agents, including doxorubicin, which induces oxidative stress (34–36). In AML, ferritin protein expression in patient samples was correlated with a response to cytarabine _in vitro_ (18). Furthermore, high ferritin levels before allogeneic stem cell transplantation have been associated with a higher risk of relapse and lower overall survival (37). With regards to the risk of relapse, this association remains unexplained and is not necessarily related to iron overload in patients who are transfused during induction and consolidation. Rather, these recent data could indicate that pre-transplantation ferritin levels are a surrogate marker of residual disease before transplantation.

If ferritin does play a role in disease progression and treatment resistance, what are the potential mechanisms for this? Ferritin is a 450 kDa protein that consists of 24 subunits of H-ferritin and L-ferritin encoded by the _FTH1_ (ferritin heavy chain 1) and _FTL_ (ferritin light chain) genes (38). Ferritin is a multi-functional protein that regulates several biological processes at both extra and intracellular levels that could be relevant in AML biology including cell proliferation, immunosuppression, angiogenesis, and chemoresistance (39). Inflammatory cytokines including IL-1β, IL-6, TNF-α, and growth factors such as insulin-like growth factor (IGF-1), which are responsible for ferritin expression through NF-kB activation, are frequently overexpressed in AML and play a crucial role in the leukemic stem cell niche (13, 29, 40, 41). In addition, extracellular ferritin could also act as a pro-inflammatory cytokine and induces NF-kB signaling (42). Therefore, ferritin synthesis induced by inflammatory cytokines could also play a role in a positive feedback loop that sustains the activation of nuclear factor-κappa B (NF-kB) in AML cells which is critical for chemoresistance and leukemic stem cell survival (43, 44). AML transcriptomic databases reveal that _FTH1_ and _FTL_ are frequently overexpressed regardless of genetic subgroup in both AML bulk and leukemic stem cells compared to normal hematopoietic stem cells. In this context, it has been shown that glioblastoma cancer stem cells are epigenetically programmed to scavenge iron more effectively than other tumor cells and require transferrin receptor and ferritin to propagate tumors (45). Ferritin is a growth factor for AML cells and its antioxidant activity may decrease the efficacy of cytotoxic agents such as anthracyclines (34, 35, 46). Moreover, H-ferritin induced by TGF-β can exert a suppressive effect on normal myelopoiesis (47). Overall, these data suggest that ferritin may impact leukemic stem cell biology within an inflammatory niche. Intracellular H-ferritin could protect AML cells from chemotherapy by inducing anti-apoptotic and anti-oxidative response while extra-cellular H-ferritin may contribute to local inflammation and alter normal bone marrow hematopoietic progenitors contributing to myelosuppression related to disease evolution and chemotherapy (48, 49).

Another point for discussion is the cellular origin of ferritin in AML, although it is thought to reside in the mononuclear phagocyte system and in hepatocytes in non-malignant conditions (50–52). Macrophages activated by an aberrant inflammatory response are likely to be the main source of serum ferritin overproduction in AML patients (50). However, a significant association was found between ferritin levels and hyperleukocytosis (tumor burden). AML cells express higher intracellular ferritin protein levels than normal peripheral blood mononuclear cells. In a previous study, leukemic cells from patients with acute monocytic leukemia (AML FAB M5) showed the highest ferritin levels (53). Furthermore, ferritin was detected in the supernatant of AML cell lines incubated in serum free media for 24 h, which suggests that AML cells may release ferritin in extra-cellular media. In addition, anthracyclines such as doxorubicin and daunorubicin may directly interact with the iron response element hairpin loops in the 5'-UTR of ferritin H- and L-chain mRNAs which could be a direct link between drug exposure and ferritin production (54). Doxorubicin has been shown to produce a significant increase in the plasma concentration of transferrin, ferritin, and iron in experimental models (55). Therefore, leukemic cells could contribute to serum ferritin production in AML patients. This hypothesis has also been suggested in previous studies (56, 57).

Accumulating evidence suggest that in AML increased serum ferritin levels are due to both a dysregulated inflammatory response and disease burden, and may have a direct impact on disease progression and response to therapy. Therefore, pharmacological modulation of this pathway could be a new therapeutic target in AML (Figure 1).

### Dexamethasone in Hyperleukocytic AML

Glucocorticoids such as dexamethasone are anti-inflammatory drugs widely used in acute lymphoblastic leukemia (ALL) and other lymphoid malignancies (58). There are only some clinical data that indicate potential action of glucocorticoids in AML. Turkish investigators previously reported their long-term experience with high-dose methylprednisolone in pediatric AML (59). Based on preclinical data showing that methylprednisolone induces AML cell differentiation and apoptosis while stimulating normal myelopoiesis, and on clinical observations of the remarkable antileukemic effect of high-dose methylprednisolone, they investigated the activity of short-term high-dose methylprednisolone treatment (20–30 mg/kg/day not exceeding 1 g/day) in childhood AML (60, 61). They were able to show that methylprednisolone when used according to this schedule as a single agent did induce leukemic cell differentiation and apoptosis in patients. Furthermore, methylprednisolone as pretreatment before high-dose chemotherapy reduced the duration and severity of neutropenia (62). However, no prospective randomized clinical trials were subsequently conducted to confirm these promising data and to generally establish glucocorticoids in the treatment of childhood AML.

In adult AML, dexamethasone has long been used to prevent or treat a severe inflammatory condition known as differentiation syndrome in patients with acute promyelocytic leukemia (APL) treated with all trans-retinoic acid (ATRA) and/or arsenic trioxide, or more recently in AML patients treated with IDH or FLT3 inhibitors (63, 64). In fact, in APL, dexamethasone (10 mg/12 h for at least 3 days) was systematically added to “3+7” + ATRA induction chemotherapy in prevention of the differentiation syndrome in all patients with a white blood cell count (WBC)
>10 G/L. Therefore, there is an established clinical experience of the use of glucocorticoids in the context of chemotherapy-induced myelosuppression in AML patients and no harmful adverse events, especially with regard to fungal invasive infections, were reported (63, 65, 66).

Approximately 20% of AML patients present with a high WBC count (>50 G/L) at diagnosis (67). This is a high-risk situation in which the probability of severe complications and early death is increased because of leukemic organ infiltration, severe hemorrhage, tumor lysis syndrome, or disseminated intravascular coagulopathy. Hyperleukocytosis is also associated with leukostasis syndrome in the lung or brain, which can lead to acute respiratory distress syndrome or stroke. Leukostasis induces endothelial injury and activation via microvascular invasion, hyperviscosity, leukocytic microthrombi, and oxygen consumption. Mediators of inflammation induced by leukemic blasts and endothelial cells play a central role in the pathogenesis of leukostasis (68). Studies on the molecular mechanisms of leukostasis and leukemic cell invasion have shown that leukemic blasts use integrins and selectins to attach to cytokine-activated endothelium and directly activate endothelial cells by secreting inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which induce the conditions necessary for their adhesion to vascular endothelium, migration to tissues, proliferation, and chemoresistance (68, 69). Because glucocorticoids exert a potent inhibitory effect on cytokine production, dexamethasone has been suggested for use in patients with AML FAB M5 and acute lung injury or acute respiratory distress syndrome who are admitted to the intensive care unit. Compared to historical controls, dexamethasone-treated patients had a significantly lower mortality rate (66). A subsequent study in adult patients admitted to the intensive care unit with respiratory events at the earliest phase of AML also showed that dexamethasone therapy was a factor independently associated with lower mortality on day 28 in the multivariate analysis (70).

![Diagram](image-url)
Moreover, a recent retrospective study that compared hyperleukocytic patients treated with intensive chemotherapy with or without a short course of dexamethasone (DEXAML-00) showed that routine addition of dexamethasone to induction chemotherapy was associated with a significant improvement in the main survival endpoints. In fact, a multivariate analysis showed that dexamethasone was significantly and independently associated with a lower incidence of relapse as well as an improvement in disease-free survival, event-free survival, and overall survival (Figure 2) (71).

**BENCH RESEARCH**

**The Mechanism of Action of Glucocorticoids**

Glucocorticoid drugs act through different targets and mechanisms to control inflammation (72). After crossing the cell membrane, glucocorticoids bind to the cytoplasmic glucocorticoid receptor (GR) and induce dissociation of molecular chaperones, including heat shock proteins and immunophilins, from the GR (73). The ligand-bound GR displays non genomic cytoplasmic activities that interfere with cell signal transduction pathways such as PI3-kinases, MAP-kinases as well as T-cell receptor signaling. Of course, the main mechanisms of action of GR are in the nucleus (74). First, as a homodimer, ligand-bound GR binds to DNA and acts as a transcription factor inducing the expression of anti-inflammatory response genes. Second, as a monomer, GR may physically interact with transcription factors such as AP-1 and NF-kB, thereby inhibiting their pro-inflammatory activities (75).

**Challenges in Using Glucocorticoids in AML**

Unlike ALL, AML blasts are not usually sensitive to pharmacologic doses of glucocorticoids (76). In vitro, it has been shown that glucocorticoids induced cell proliferation in some pediatric AML.

---

**FIGURE 2** | The main results of the DEXAML-00 retrospective study in hyperleukocytic acute myeloid leukemia (AML) patients. Graphical abstract by Haematologica showing the endpoints of a retrospective, monocentric study comparing the addition of dexamethasone to standard induction chemotherapy in AML patients with hyperleukocytosis defined as a white blood cell count ≥50 × 10⁹/L. From 2010 to 2015, 60 patients received dexamethasone (10 mg/12 h, days 1–3) and were compared to 100 patients who did not received dexamethasone from 2004 to 2009. In multivariate analysis, dexamethasone was associated with a significant improvement of disease-free, event-free and overall survival.
samples (77). Moreover, a recent study focusing on both BCR-ABL positive ALL and chronic myelocytic leukemia cells demonstrated that strong differences in energetic metabolism driven by B-cell lineage transcription factors explain the difference in glucocorticoid sensitivity between lymphoid and myeloid cells (78). The B-lymphoid transcription factors, PAX5 and IKZF1, which are crucial for early B cell development and repressed in myeloid cells, induce a transcriptional program leading to a state of chronic energy deprivation by restricting glucose uptake. This establishes a metabolic barrier to the leukemogenesis of ALL. This transcriptional program is also associated with up regulation of glucose uptake inhibitors expression including NR3C1 thereby contributing to ALL sensitivity to glucocorticoids. Moreover, mechanisms of resistance to glucocorticoids that has been extensively studied in ALL may also occur in AML cells including alterations in uptake and efflux by multidrug transporters, GR expression or in downstream apoptotic response (79, 80). Indeed, the regulation of expression of BCL2 family proteins such as the proapoptotic BIM and the anti-apoptotic BCL2 or MCL1 is key to determine the level of glucocorticoid sensitivity (81).

In clinic, glucocorticoids may increase the risk of bacterial or invasive fungal infections by worsening the immunosuppression of AML patients during intensive chemotherapy. Therefore, these drugs have received little attention in the invasive fungal infections by worsening the immunosuppression of AML patients during intensive chemotherapy. Therefore, these drugs have received little attention in the development of AML patients during intensive chemotherapy. Therefore, these drugs have received little attention in the development of AML cell lines to 446 FDA approved drugs compared to 77 AML, dexamethasone decreased the activity of deoxycytidine kinase. However, it should be noted that in a rat model of AML, dexamethasone decreased the activity of deoxycytidine kinase (83). Meanwhile, in a similar study, the response of 2 DCK-defective murine AML cell lines to 446 FDA approved drugs compared to their cytarabine sensitive parental lines was examined. Once again, cytarabine-resistant cells that lacked functional deoxycytidine kinase were sensitive to prednisolone and dexamethasone in a GR-dependent manner (84). Overall, these studies showed that mechanisms that lead to cytarabine resistance may be linked to the acquisition of dexamethasone sensitivity.

Chemoresistance is also mediated by interactions between AML cells and their microenvironment (85–87). It has been recently demonstrated that an inflammatory and immune interferon-γ signature is associated with chemoresistance (88). In liquid culture, short term dexamethasone treatment with or without cytarabine or doxorubicin showed no synergy or additive effect in genetically diverse AML cell lines. However, in a co-culture system, one week of dexamethasone exposure significantly enhanced cytarabine activity in most AML cell lines, which indicates that glucocorticoids may interfere with soluble factors or cellular interactions involved in microenvironment-induced resistance (71, 89). Furthermore, using a patient-derived xenograft (PDX) model of cytarabine resistance, it was shown that the transcriptome of residual AML cells that were resistant to cytarabine treatment in vivo was highly enriched in genes involved in inflammatory and immune response, including the NF-kB network (71, 90). This gene signature of in vivo chemoresistance also displayed significant interactions with the dexamethasone gene signature for FCGR1A, IL6ST, BIRC3, HGF, IL2RA, HDC, RHAG, STAT4, CALCRL, CD200, and CSF1 genes. Similarly, examination of a publicly available transcriptomic data set established from AML patients in first relapse and data mining algorithm revealed that the dexamethasone signature was also enriched within AML cells collected at relapse (71, 91). Moreover, in PDX models the dexamethasone-cytarabine combination induced a stronger therapeutic response compared to cytarabine alone. Overall, these data strongly suggest that the impact of dexamethasone with intensive chemotherapy that is observed in clinical practice could result from the targeting of inflammatory chemoresistant AML cells.

The Action of Glucocorticoids in Chemoresistance

The unexpected impact of dexamethasone observed on the cumulative incidence of relapse suggests a potential antileukemic activity on chemoresistant AML cells (71). In a recent preclinical study, AML cell lines were rendered resistant to cytarabine through chronic exposure to increasing drug concentrations then subjected to genomic and transcriptomic profiling as well as high-throughput testing with 250 clinical oncology compounds (82). It was shown that the acquisition of cytarabine resistance was associated with increased sensitivity to glucocorticoids. Similarly, paired samples from AML patients, while unresponsive at diagnosis, became sensitive to glucocorticoids including dexamethasone, methylprednisolone, and prednisolone at relapse after exposure to a cytarabine-based chemotherapy regimen. In this study, glucocorticoid activity was mainly observed in wild type FLT3 samples whereas mutated FLT3-ITD samples appeared resistant. Resistance to cytarabine was associated with deletion of the DCK gene that encodes deoxycytidine kinase, the rate-limiting enzyme in the metabolic activation of cytarabine. Moreover, upregulation of GR protein expression was also observed in cytarabine-resistant AML cells and contribute to the acquisition of glucocorticoid sensitivity. However, it should be noted that in a rat model of AML, dexamethasone decreased the activity of deoxycytidine kinase (83). Meanwhile, in a similar study, the response of 2 DCK-defective murine AML cell lines to 446 FDA approved drugs compared to their cytarabine sensitive parental lines was examined. Once again, inflammatory cytokines can...
induce both NF-kB and AP-1 to support leukemic stem-cell survival in a synergistic manner (44). Therefore, by suppressing cytokine release and targeting specific intracellular pathways, dexamethasone may interfere with leukemic stem cell behavior and make them more susceptible to chemotherapy-induced cell death. Of course, the mechanisms of action underpinning dexamethasone activity in AML are likely to be multiple as leukemic stem cells are subject to different levels of regulation that are either cell autonomous or driven by interactions with the microenvironment (41, 96).

The Action of Glucocorticoids in AML Subgroups

RUNX1-RUNX1T1

AML with t(8;21) translocation is induced by the oncogenic activity of the RUNX1-RUNX1T1 fusion gene generated by chromosomal translocation and represents approximatively 10% of AML. The RUNX1-RUNX1T1 oncoprotein acts as a dominant negative regulator of RUNX1 transcriptional activity thereby repressing the expression of RUNX1-dependant genes involved in myeloid differentiation (97, 98). RUNX1-RUNX1T1 also promotes self-renewal of leukemic stem cells (99). In a chemogenomic screening of a small molecule library, two classes of compounds (glucocorticoids and dihydrofolate reductase inhibitors) were found to abrogate the RUNX1-RUNX1T1 gene expression signature (100). Methylprednisolone and dexamethasone used at nanomolar concentrations induced cell differentiation and apoptosis in the Kasumi-1 cell line and the U937 cell line engineered to express RUNX1-RUNX1T1 but not in other AML cell lines that do not express the oncoprotein. Glucocorticoid treatment was associated with a significant reduction in RUNX1-RUNX1T1 protein expression which was reverted by proteasome inhibitors, suggesting that glucocorticoids promote proteasome-mediated RUNX1-RUNX1T1 protein degradation. Of note, methylprednisolone treatment was associated with a down regulation of BCL-2 expression in this study and other investigators also found that dexamethasone down regulated BCL-X L in the U937 cell line, which indicates that glucocorticoids may alter key anti-apoptotic molecules in myeloid cells (101). A more recent study also showed that glucocorticoid drugs can mimic RUNX1-RUNX1T1 knock-down and induce both the inhibition of RUNX1-RUNX1T1-mediated gene expression and the stimulation of transcriptional activity of wild type RUNX1 allele. Dexamethasone inhibited self-renewal of LICs and induced significant differentiation and apoptosis of RUNX1-RUNX1T1 AML cells (102). Moreover, dexamethasone used as a single agent inhibited tumor growth and prolonged the survival of mice engrafted with the Kasumi-1 cell line. Investigators proposed a mechanism of action by which glucocorticoids increased the amount of ligand-bound glucocorticoid receptors in the nucleus as well as their binding to DNA and RUNX1-RUNX1T1 target gene promoters. Interaction between glucocorticoid receptors and RUNX1 (but not RUNX1-RUNX1T1) increased RUNX1 binding to its target genes and decreased RUNX1-RUNX1T1 binding. The unbound RUNX1-RUNX1T1 might be subjected to proteasome-mediated degradation, resulting in a reduced level of oncoproteins in the nucleus. This leads to a significant change in gene expression with RUNX1 dominance over RUNX1-RUNX1T1 promoting RUNX1-mediated hematopoietic differentiation and inhibition of RUNX1-RUNX1T1-mediated stem cell maintenance. In addition, a combination of dexamethasone with cytorebin or doxorubicin was synergistic in this AML cell line, which suggests that combining dexamethasone with “3+7” induction and then with high-dose cytorebin during the consolidation phase could be a treatment option to be explored in patients with t(8;21)/RUNX1-RUNX1T1 AML (100, 102). It is also noteworthy that dexamethasone activity was stronger than prednisolone or hydrocortisone activity (102, 103).

RUNX1 Mutations

AML with mutated RUNX1 (RUNX1mut AML) is a provisional entity that accounts for 10% of the newly diagnosed patients and is associated with a poor prognosis (104–107). In fact, RUNX1mut AML is included in the high-risk group of the ELN 2017 classification. RUNX1 mutations are frequently encountered in AML with minimal differentiation (AML-M0), normal karyotype or noncomplex karyotype with frequent association with trisomy 13. RUNX1 mutations are mutually exclusive of recurrent translocations in AML and co-occur with ASXL1 mutations and other gene mutations including epigenetic modifiers (IDH2, KMT2A, EZH2), spliceosome complex (SF3B1, SRSF2, SF3B1) and STAG2, PHF6, and BCOR (107). The RUNX1 mutation–associated gene and microRNA expression signatures revealed that the most strongly upregulated genes were related to hematopoietic stem/progenitor cells and/or B-cell progenitors, whereas genes normally expressed in myeloid-committed cells including CEBPA were among the most downregulated (108, 109). A recent study demonstrated that the RUNX1 allele dosage may determine the RUNX1 mutation–associated gene expression signature and identified a distinct RUNX1mut AML subgroup with significant association with FAB M0 morphology, trisomy 13, and ASXL1 mutations, whereas a chemogenomic approach revealed that AML samples bearing inactivating mutations of RUNX1 were particularly sensitive to nanomolar concentrations of glucocorticoids (110). AML samples with dominant negative or RUNX1 fusion mutations (lacking the wild type allele) were much more responsive to glucocorticoids than AML sample wild type RUNX1 allele or with missense RUNX1 mutations, which are known to have no impact on RUNX1 function. Furthermore, down-regulation of RUNX1 expression was associated with acquired dexamethasone sensitivity. Glucocorticoid sensitivity was reverted by the GR antagonist RU486 or NR3C1 expression was associated with acquired dexamethasone sensitivity. Glucocorticoid sensitivity was reverted by the GR antagonist RU486 or NR3C1 mutations, which are known to have no impact on RUNX1 function. Furthermore, down-regulation of RUNX1 expression was associated with acquired dexamethasone sensitivity. Glucocorticoid sensitivity was reverted by the GR antagonist RU486 or NR3C1 mutations, which are known to have no impact on RUNX1 function. Furthermore, down-regulation of RUNX1 expression was associated with acquired dexamethasone sensitivity. Glucocorticoid sensitivity was reverted by the GR antagonist RU486 or NR3C1 mutations, which are known to have no impact on RUNX1 function. Furthermore, down-regulation of RUNX1 expression was associated with acquired dexamethasone sensitivity.
there is no clinical data showing that glucocorticoids have an impact on RUNXI\textsuperscript{mut} AML.

**NPM1 Mutations**

Mutations in the nucleophosmin (NPM1) gene are among the most frequent molecular alterations in AML (~35%) and represent a distinct entity in AML according to the 2016 WHO classification (112, 113). When the karyotype is normal and FLT3-ITD mutation is not associated or weakly expressed, NPM1 mutation indicates a favorable outcome in AML according to the ELN 2017 prognosis classification even though the co-mutational environment may further influence this prognostic impact (6, 114). Unmutated NPM1 protein is mainly located in the nucleus and plays a key role in the regulation of ribosome biogenesis, nucleolar function, protein synthesis, and tumor suppression by activating the TP53 pathway. Mutated NPM1 loses its predominant nucleolar location and accumulates in the cytoplasm thereby inducing leukemogenesis through HOX gene activation (115).

OCI-AML3, a NPM1 mutated cell line, demonstrated in vitro and in vivo sensitivity to dexamethasone compared to wild type cell lines and primary AML samples with NPM1 mutation were also more sensitive to dexamethasone-induced apoptosis than wild type samples (71, 110). Although, the mechanisms of action that sustain this particular sensitivity have not been described, in silico exploratory analyses showed that the NPM1 mutation gene signature was highly enriched in genes responsive to dexamethasone, including upregulated genes such as GGT1, CD86, NAMPT, ETS2, NFKBIA, PLA2G4A, IL1B, CD163, FPR1, HIST1H1C, CCL1, CXCL2, PTX3, TNF, RHAG, CCL20, DEFB1, CD300C, HOXB5, and IL6 (71).

**FLT3 Mutations**

Mutations in the FLT3 gene are also frequent mutations in AML that occur in up to 30% of patients (114). Two distinct FLT3 mutations that induce constitutive ligand-independent activation of kinase are described: internal tandem duplications (ITD) in the juxtamembrane domain and point mutations in the tyrosine kinase domain (TKD). FLT3 mutations are associated with an aggressive disease course especially FLT3-ITD which predicts early relapse and a poor prognosis. Through clonal selection under chemotherapy, a higher mutant allelic burden is frequently observed at relapse, which indicates that AML cells have become more addicted to FLT3 signaling. In the preclinical setting, FLT3-mutant allelic burden and clinical status (diagnosis versus relapse samples) are predictive of a response to FLT3 inhibitors in AML (116). Furthermore, FLT3-ITD is also an independent factor of a poor prognosis in R/R AML (117, 118). Recently, two class I FLT3 inhibitors that target both FLT3-ITD and FLT3-TKD mutations were approved for the treatment of AML with FLT3 mutation. Midostaurin was approved in combination with intensive chemotherapy as a first line treatment whereas gilteritinib was approved as a single agent treatment in relapsed or refractory patients (119, 120).

A very recent study aimed at describing the mechanisms of early acquired resistance to FLT3 inhibitors showed that AML cells with FLT3-ITD mutations that persist after 48 h of FLT3 inhibitor drug exposure (drug-tolerant persisters) up-regulated both the inflammatory response gene and GR expression. This resulted in synergistic activity of the combination of FLT3 inhibitors and glucocorticoids through apoptosis induction both in vitro and in xenotransplantation mice models (121). This very rapid and transient resistance mechanism was specific to FLT3 mutated cells and not due to the selection of resistance-conferring mutation or the reactivation of FLT3 signaling. Rather, it was dependent on the up-regulation of GC receptor expression upon FLT3i exposure and the increased BIM to MCL1 ratio upon combination treatment. To be more specific, BIM expression was strongly up-regulated by glucocorticoids whereas MCL1 was down-regulated by FLT3i through GSK-mediated activation of the proteasome pathway and MCL1 protein degradation. This preclinical study should stimulate clinical trials in this setting since the complete response rate with the recently approved gilteritinib is < 50%.

**Spliceosome-Complex Mutations**

Genes of the spliceosome-complex including SRSF2, SF3B1, U2AF1, and ZRSR2 are frequently mutated in myeloid malignancies such as AML, myelodysplastic syndromes (MDS) or myeloproliferative disorders (122). In AML, they are particularly found in patients with a history of MDS or chronic myelomonocytic leukemia (secondary AML) (123). These mutations induce neomorphic or gain-of-function splicing phenotypes and alter the splicing of many genes (124). Recently, it was shown that an increase in inflammatory cytokine production including IL-6, IL-8, TNF-\(\alpha\), and NF-kB activation is found in leukemic cells harboring spliceosome mutations (125–127). Moreover, SRSF2-mutated AML samples also expressed an increase in the level of NR3CI and were responsive to glucocorticoid treatment (110). However, the activity of glucocorticoids on other spliceosome-complex mutations has not been assessed to date.

**PERSPECTIVES: WILL THERE BE A PLACE FOR DEXAMETHASONE IN AML TREATMENT?**

These recent studies indicate the role of inflammation in AML biology. Under specific oncogenic (RUNXI, NPM1, or SRSF2 mutations and NF-kB activation in LSCs) or therapeutic (cytarabine and FLT3 inhibitors) stress, AML displays up-regulation of the inflammation gene response and GR expression that induces sensitization to glucocorticoid therapeutic action partially through the modulation of key apoptotic protein (Figure 3). Whether other oncogenes involved in AML such as IDH1/2, TP53, KMT2A, or EVI-1 or other treatments including hypomethylating agents or BCL2 inhibitors may also induce inflammatory phenotypes remains to be determined. Therefore, although the glucocorticoid unresponsiveness of AML bulk is an established preclinical and clinical fact which to date has precluded clinical investigations on AML unlike ALL, some AML molecular subgroups or cell subpopulations could benefit from therapeutic
intervention with glucocorticoids. Therefore, the French cooperative FILO study group designed three prospective clinical trials in the field (Figure 4).

**Dexamethasone in Hyperleukocytic AML (DEXAML-00)**

AML patients with a high white blood-cell count are difficult to manage, require immediate chemotherapy induction, and therefore are often excluded from prospective trials. In the retrospective DEXAML-00 study in patients with hyperleukocytic AML, the impact of dexamethasone on all survival endpoints and the incidence of relapse, was adjusted according to several clinical and biological factors to limit the potential biases inherent in non-randomized studies (71). As indicated above, dexamethasone may also be of benefit in critically-ill AML patients (66, 70, 128, 129). Therefore, many French centers, including ours, are accustomed to treating all patients with a white blood cell count >50 G/L with a short course of dexamethasone in combination with chemotherapy. Previous studies on dexamethasone pharmacokinetics have shown that plasma levels achieved in dosed patients with this schedule are likely to reach therapeutic concentrations used in preclinical AML models (130, 131). Moreover, relevant logical biological bases strengthened these retrospective clinical findings and paved the way to further explore dexamethasone action in other situations besides hyperleukocytic AML.

**Dexamethasone With High-Dose Cytarabine as Post-Remission Therapy in Younger AML Patients (DEXAML-01)**

Based on preclinical evidence showing increased sensitivity to glucocorticoids in cytarabine-resistant cells and in LSC’s assumed to be at the origin of relapse, dexamethasone is currently being tested in a phase II-III randomized trial within the French ALFA/FILO backbone intergroup-1 trial (BIG-1, NCT02416388). Younger patients (18–60 years) with favorable or intermediate risk AML, in their first complete remission following standard induction chemotherapy, receive either high-dose cytarabine alone (standard of care) or high-dose cytarabine plus dexamethasone (Figure 4). The primary objective is to improve leukemia-free survival with the addition of dexamethasone. To date, 178 patients have been randomized and recruitment should be completed during the first half of 2021 for a total of 220 patients. The final analysis will be performed 18 months after the last inclusion.
Dexamethasone With Intensive Chemotherapy as First-Line Therapy in Older AML Patients (DEXAML-02)

The FILO study group induction chemotherapy for newly diagnosed AML patients older than 60 is a 3-drug regimen including idarubicin, cytarabine, and lomustine (ICL) (132). The DEXAML-02 trial is a prospective, single arm, phase 2 trial that evaluates the addition of dexamethasone during both induction and consolidation (NCT03609060). The primary objective is to determine whether adding dexamethasone to ICL induction and IC post-remission therapy results in significant improvement of event-free survival compared with a historical cohort of the FILO.
LAM-SA 2007 trial (132). Of note, midostaurin is added in FLT3 mutated patients. FILO was not able to conduct a randomized trial versus placebo since the proposal was not considered a high enough priority by the national clinical research funding agency. Recruitment of the 120 patients ended in early 2020. Ancillary studies on leukemic stem cells, immune subpopulations and cytokine production subsequent to treatment are planned. The final analysis will be performed in 2022.

**Dexamethasone With Intensive Salvage Chemotherapy or Azacitidine in Relapsed/Refractory AML (DEXAML-03)**

AML patients who fail to achieve a complete response with standard induction therapy (refractory AML) or who relapse after achieving remission have a very poor prognosis (133). Treatment of relapsed or refractory (R/R) AML in patients who are candidates for intensive salvage chemotherapy consists of reducing the leukemia burden in order to achieve remission before allogeneic stem-cell transplantation, which is currently the treatment with the highest probability for cure. The prognosis is even more dismal in patients deemed unfit for intensive chemotherapy. Non-intensive approaches including hypomethylating agents are generally proposed in this context (134).

As indicated above, AML samples collected at relapse are much more sensitive to glucocorticoids than diagnosis samples (82, 84). Moreover, preclinical studies have shown that the gene signature of cells resistant to hypomethylating agents is also enriched with dexamethasone response genes (135). In addition, in ALL cell lines, azacitidine has been shown to restore GR expression and sensitivity to dexamethasone (136). Therefore, a randomized phase 3 clinical trial was designed to assess the impact of dexamethasone added to either intensive chemotherapy or azacitidine, according to the investigator’s choice, in adult patients with R/R AML (NCT03765541). The primary objective is to evaluate whether the addition of dexamethasone to salvage therapy significantly improves overall survival. This study is ongoing.

**CONCLUSION**

Repositioning approved drugs for other indications is an interesting subject for clinical trials by cooperating study groups (137). Even though glucocorticoids have received little attention in AML, the evidence in this review provides a basis for clinical assessment of whether glucocorticoids such as dexamethasone can one day be included in the AML treatment armamentarium. A panel of 79 myeloid genes will be screened by next-generation sequencing in the DEXAML studies to explore the clinical benefit of dexamethasone in specific subgroups as suggested by several preclinical studies. If the results of these clinical trials are positive, they could be easily and widely incorporated into routine practice since hematologists have long experience with this drug in lymphoid malignancies.

**AUTHOR CONTRIBUTIONS**

The author confirms being the sole contributor of this work and has approved it for publication.

**FUNDING**

Funding from the Fondation Toulouse Cancer Santé, Force Hémato (AO 2017), the French Ministry of Health (PHRC interrégional 2017) and the Ligue Régionale Contre le Cancer (AO 2018).

**REFERENCES**

1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. *N Engl J Med* (2015) 373(12):1136–52. doi: 10.1056/NEJMra1406184
2. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. *Blood* (2016) 127(1):53–61. doi: 10.1182/blood-2015-08-604520
3. Miyamoto K, Minami Y. Cutting Edge Molecular Therapy for Acute Myeloid Leukemia. *Int J Mol Sci* (2021) 21(14):5144. doi: 10.3390/ijms21145114
4. Wei AH, Tiong IS. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. *Br J Haematol* (2017) 188(3):424–47. doi: 11.1088/blood-2016-08-733196
5. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* (2017) 129(4):424–47. doi: 11.1088/blood-2016-08-733196
6. Dohner H, Weisdorf DJ, et al. Genomic classification and prognosis of acute myeloid leukemia. *Blood* (2016) 127(23):2209–21. doi: 10.1056/NEJMoa1516192
7. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* (2013) 368(22):2059–74. doi: 10.1056/NEJMoa1301689
8. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. *Cell* (2012) 150(2):264–78. doi: 10.1016/j.cell.2012.06.023
9. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. *Nature* (2012) 481(7382):506–10. doi: 10.1038/nature10738
10. Jongen-Lavrencic M, Grob T, Haneke D, Kavelaars FG, Al Hinai A, Zeleznik A, et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. *N Engl J Med* (2018) 378(13):1189–99. doi: 10.1056/NEJMoa1716865
11. Yamashita M, Dellorusso PV, Olson OC, Passegué E. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. *Nat Rev Cancer* (2020) 20(7):365–82. doi: 10.1038/s41568-020-0260-3
12. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell* (2011) 144(5):646–74. doi: 10.1016/j.cell.2011.02.013
13. Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. *Blood* (2017) 130(15):1693–8. doi: 10.1182/blood-2017-06-780882
14. Gonen C, Celik I, Cetinkaya YS, Haznedaroglu I. Cytarabine-induced fever complicating the clinical course of leukemia. *Anticancer Drugs* (2005) 16(1):59–62. doi: 10.1097/00001813-200501000-00008
15. Chng WJ. Cytarabine syndrome revisited. *Br J Haematol* (2003) 122(6):875. doi: 10.1046/j.1365-2141.2003.04422.x
16. Ek T, Jarfelt M, Mellander I, Abrahamsson J. Proinflammatory cytokines 
mediate the systemic inflammatory response associated with high-dose 
cytarabine treatment in children. Med Pediatr Oncol (2001) 37(3):459–64. 
doi: 10.1002/(ISSN)1098-103X.
17. Ek T, Pinkava M, Abrahamsson I. A-A-C fever and infections after high-dose 
ara-C treatment in pediatric lymphoid malignancies. Pediatr Hematol Oncol (2005) 27(7):364–9. 
doi: 10.1097/01.mph.0000173176.33271.8f.
18. Bertoli S, Paubelle E, Berard E, Saland E, Thomas X, Tavitian S, et al. Ferritin 
heavy/light chain (FTH1/FTL) expression, serum ferritin levels and their 
functional as well as prognostic roles in acute myeloid leukemia. Eur J Haematol (2019) 102(2):131–42. 
doi: 10.1111/ejh.13183.
19. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the 
adult patient. Blood (2015) 125(19):2908–14. doi: 10.1182/blood-2015-01-551622.
20. La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, 
Berliner N, et al. Recommendations for the management of hemophagocytic 
lymphohistiocytosis in adults. Blood (2019) 133(23):2465–77. doi: 10.1182/ 
blood.2018189418.
21. Delavigne K, Berard E, Bertoli S, Corre J, Duchayne E, Demur C, et al. 
Hemophagocytic syndrome in patients with acute myeloid leukemia 
undergoing intensive chemotherapy. Haematologica (2014) 99(3):474–80. 
doi: 10.3324/haematol.2013.097394.
22. Perricone C, Bartoloni E, Bursi R, Cafaro G, Guidelli GM, Shoenfeld Y, et al. 
COVID-19 as part of the hyperferritinemic syndromes: the role of iron 
depletion therapy. Immunol Res (2020) 68(4):213–24. doi: 10.1007/s12026- 
020-09145-5.
23. Cheng L, Li H, Li L, Liu C, Yan S, Chen H, et al. Ferritin in the coronavirus 
disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Lab 
Anal (2020) 34(10):e23618. doi: 10.1111/jcla.2020.e23618.
24. Ruscitti P, Berardicurti O, Di Benedetto P, Cipriani P, Iagnocco A, Shoenfeld 
Y, et al. Severe COVID-19, Another Piece in the Puzzle of the 
Hyperferritinemic Syndrome. An Immunomodulatory Perspective to 
Alleviate the Storm. Hyperferritinemia at diagnosis predicts relapse and overall survival in 
primary human acute myeloid leukemia cells. Blood (2001) 98(8):2301–7. doi: 10.1182/ 
blood.v98.8.2301.
25. Hemmati S, Haque T, Gritsman K. Cytokine pro 
sumption of Interleukin-1 by Functional Screening as a Key Mediator of 
Inflammatory cytokines 
control of granulocytic stem cells by inhibitory activity derived 
through a nonclassical secretory pathway. J Exp Med (2018) 215(6):1709– 
21. doi: 10.1084/jem.20180147.
26. Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute 
leukemia. Front Oncol (2015) 5(3):2790–6. doi: 10.3389/ 
frontiersin.org.2015.02520.
27. Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Bañas H, 
Hasegawa S, Morokoshi Y, Kanda H, Tsukamoto S, Zheng J, Tsuji AB, et al. 
H-ferritin overexpression promotes radiation-induced leukemia/lymphoma 
in mice. Carcinogenesis (2012) 33(11):2269–75. doi: 10.1093/carcin/bgs251.
28. Armand P, Kim HT, Virnani JM, Parkkola RK, Ita-Rames MA, Majhail NS, et al. Iron 
overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant (2014) 20(8):1248– 
51. doi: 10.1016/j.bbmt.2014.04.024.
29. Alkhateeb AA, Connor JR. Nuclear ferritin: A new role for ferritin in cell 
biology. Biochim Biophys Acta (2010) 1800(8):793–7. doi: 10.1016/ 
bj.bbaben.2010.03.017.
30. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the 
adult patient. Blood (2015) 125(19):2908–14. doi: 10.1182/blood-2015-01-551622.
31. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the 
adult patient. Blood (2015) 125(19):2908–14. doi: 10.1182/blood-2015-01-551622.
32. Perricone C, Bartoloni E, Bursi R, Cafaro G, Guidelli GM, Shoenfeld Y, et al. 
COVID-19 as part of the hyperferritinemic syndromes: the role of iron 
depletion therapy. Immunol Res (2020) 68(4):213–24. doi: 10.1007/s12026- 
020-09145-5.
33. Ihlow J, Gross S, Sick A, Schneider T, Flöcken A, Burmeister T, et al. AML: 
high serum ferritin at initial diagnosis has a negative impact on long-term survival. Leuk Lymphoma (2019) 60(1):69–77. doi: 10.1080/10428194. 
2018.1461860.
54. Canzoneri JC, Oyelere AK. Interaction of anthracyclines with iron responsive element mRNAs. Nucleic Acids Res (2008) 36(21):6825–34. doi: 10.1093/nar/gkn774

55. Othman AI, El-Missiry MA, Amer MA, Araf M. Melatonin controls oxidative stress and modulates iron, ferritin, and transferrin levels in amichy treated rats. Life Sci (2008) 83(15-16):563–8. doi: 10.1016/j.lfs.2008.08.004

56. Aulbert E, Fromm H, Hornemann H. Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia. Med Klin (Munich) (1991) 86(6):297–304.

57. Wahlin A, Hörnsten P, Jonsson H. Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur J Haematol (1991) 46(4):240–7. doi: 10.1111/j.1600-0609.1991.tb0547x

58. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol (2010) 11(11):1096–106. doi: 10.1016/S1470-2045(10)70114-5

59. Hícsonmez G. The effect of steroid on myeloid leukemia cells: the potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelopoiesis. Leuk Res (2006) 30(1):60–8. doi: 10.1016/j.leukres.2005.05.015

60. Hícsonmez G, Cetin M, Aslan D, Ozyurek E. The role of short course of high-dose methylprednisolone in children with acute myeloblastic leukemia (FAB M2) presented with myeloid tumor. Pediatr Hematol Oncol (2003) 20(5):373–9. doi: 10.10880/088001390203954

61. Hícsonmez G, Karadeniz N, Zanmani VP, Tuncer AM, Gumruk F, Ertuk G, et al. High remission rate in acute myeloblastic leukemia in children treated with high-dose methylprednisolone. Eur J Haematol (1992) 48(4):215–20. doi: 10.1111/j.1600-0609.1992.tb01588.x

62. Cetin M, Hícsonmez G, Tuncer AM, Kansu E, Canpynar H. The effect of short-course high-dose corticosteroid therapy on peripheral blood CD34+ progenitor cells in children with acute leukemia. Exp Hematol (1996) 24(10):1191–4.

63. Kelaïdi C, Chevret S, De Botton S, Rafioux E, Guerci A, Thomas X, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol (2009) 27(16):2666–76. doi: 10.1200/JCO.2008.18.4119

64. Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood (2014) 123(18):2777–82. doi: 10.1182/blood-2013-10-512640

65. Kelaïdi C, Adès L, Fenaux P. Treatment of acute promyelocytic leukemia with high white cell blood counts. Mediterr J Hematol Infect Dis (2011) 3(1):e2011038. doi: 10.4084/mjhid.2011.0038

66. Azoulay É, Canet E, Rafioux E, Lenglé E, Lemiale V, Vincent F, et al. Dexamethasone in patients with acute lung injury from acute monocytic leukaemia. Eur Respir J (2012) 39(3):648–53. doi: 10.1183/09031936.0005771

67. Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood (2015) 125(21):3246–52. doi: 10.1182/blood-2014-10-551507

68. Stucki A, Rivier AS, Gikis M, Monai N, Schapira M, Spertino O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood (2001) 97(7):2121–9. doi: 10.1182/blood.V79.7.2121

69. Griffin JD, Rambaldi A, Vellenga E, Young DC, Ostapovich D, Cannistra SA. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood (1987) 70(4):1218–21. doi: 10.1182/blood.V70.4.1218.bloodjournal8701218

70. Moreau A-S, Lengline E, Seguin A, Lemiale V, Canet E, Rafioux E, et al. Respiratory events at the earliest phase of acute myeloid leukemia. Leuk Lymphoma (2014) 55(11):2556–63. doi: 10.3109/10428194.2014.887709

71. Bertoli S, Picard M, Berard E, Griesinger E, Larrue C, Mouchel PL, et al. Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica (2018) 103(6):988–98. doi: 10.3324/haematol.2017.184267

72. Löwenberg M, Stah H, Connies DW, Buttgeri F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids (2008) 73(9-10):1025–9. doi: 10.1016/j.steroids.2007.12.002

73. Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol (2010) 120(2-3):69–75. doi: 10.1016/j.jsbmb.2010.03.058
92. Griesinger E, Anjos-Afonso F, Vargaftig B, Taussig DC, Lassaillly F, Prebet T, et al. Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. Cancer Res (2016) 76(8):2082–6. doi: 10.1158/0008-5472.CAN-15-2063

93. Lavenderie I, Boileu M, Neumann AL, Frison H, Mitchell A, Ng SWK, et al. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Blood Cancer J (2018) 8(6):52. doi: 10.1038/s41408-018-0087-2

94. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science (2009) 324(5953):1670–3. doi: 10.1126/science.1171837

95. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 146(5):697–708. doi: 10.1016/j.cell.2011.07.032

96. Schepers K, Campbell TR, Passegge E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell (2015) 16(3):254–67. doi: 10.1016/j.stem.2015.02.014

97. Peterson LF, Zhang DE. The 8:21 translocation in leukaemogenesis. Oncogene (2004) 23(24):4525–62. doi: 10.1080/0140076041000173202

98. Lin S, Mulloy JC, Goyama S. RUNX1-ETO Leukemia. Leukemia (2009) 23(22):6969–708. doi: 10.1038/leu.2009.214

99. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukemia. Blood (2009) 113(24):6193–9. doi: 10.1182/blood-2009-11-255976

100. Corsello SM, Roti G, Ross KN, Chow KT, Galinsky I, DeAngelo DJ, et al. Glucocorticoids Inhibit RUNX1 allele dosage in genetics and glucocorticoid sensitivity. Clin Cancer Res (2017) 23(22):6969–81. doi: 10.1186/1740-8421-13-1259

101. Adnan Awad S, Dufva O, Ivanek S, Ghimire B, Koski J, Maliniemi P, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia (2020) doi: 10.1038/s41375-020-01011-3

102. Falini B, Martelli MP, Bolli N, Sportelli P, Liso A, Tacci E, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood (2011) 117(4):1109–20. doi: 10.1182/blood-2010-08-299990

103. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood (2016) 127(20):2391–405. doi: 10.1182/blood-2016-03-643544

104. Papaemmanuili E, Dohner H, Campbell PJ. Genomic Classification in Acute Myeloid Leukemia. N Engl J Med (2016) 375(9):900–1. doi: 10.1056/NEJMoa1608739

105. Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood (2020) 136(15):1707–21. doi: 10.1182/blood.2019004226

106. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood (2010) 115(7):1425–32. doi: 10.1182/blood-2009-09-242859

107. Chevalier P, Prebet T, Aunan M, Delaunay J, Perry F, et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Ann Oncol (2018) 29(5):742–9. doi: 10.1093/annonc/mdy058

108. Bergua JM, Montesinos P, Martinez-Cuadrón D, Fernandez-Abellan P, Serrano J, Sayas MF, et al. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/refractory acute myeloid leukemia. Br J Haematol (2016) 174(5):701–10. doi: 10.1111/bjh.14107

109. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med (2017) 377(5):545–64. doi: 10.1056/NEJMoa1614399

110. Perl AE, Martellini G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med (2019) 381(18):1728–40. doi: 10.1056/NEJMoa1902688

111. Gebru MT, Atkinson JM, Young MM, Zhang L, Tang Z, Liu Z, et al. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. Blood (2020) 136(9):1067–79. doi: 10.1182/blood19030124

112. Taylor J, Lee SC. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies. Genes Chromosomes Cancer (2019) 58(12):889–902. doi: 10.1002/gcc.22784

113. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Consensus genetic and clinical analysis from the AML study group. J Clin Oncol (2011) 29(10):1364–72. doi: 10.1200/JCO.2010.30.7926

114. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood (2011) 117(8):2348–57. doi: 10.1182/blood-2011-05-355976

115. Gaidzik VI, Leleuvau V, Papaemmanuil E, Weber D, Paschka P, Hahn J, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia (2016) 30(11):2160–8. doi: 10.1038/leu.2016.126

116. Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol (2012) 30(25):3109–18. doi: 10.1200/JCO.2011.40.6652

117. Silva FP, Swagemakers SM, Erpelinck-Verscheuren C, Wouters BJ, Delwel R, Vrielin H, et al. Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. Blood (2009) 114(14):3001–7. doi: 10.1182/blood-2009-03-211354

118. Simon J, Lavallee VP, Bordeleau ME, Krepl J, Baccelli J, Boucher G, et al. Chromosome synopsis of RUNX1-mutated AML reveals importance of RUNX1 allele dosage in genetics and glucocorticoid sensitivity. Clin Cancer Res (2017) 23(22):6969–81. doi: 10.1158/1078-0432.CCR-17-1259

119. Motta N, Issa N, Dumas P-Y, Camou F, Saucie M, Gros F-X, et al. Reduce Mortality and Morbidity in Acute Myeloid Leukemia With Hyperleucytosis With Early Admission in Intensive Care Unit: A Retrospective Analysis. J Hematol (2020) 9(4):109–15. doi: 10.14740/jh691
130. O’Sullivan BT, Cutler DJ, Hunt GE, Walters C, Johnson GF, Caterson ID. Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. *Biol Psychiatry* (1997) 41(5):574–84. doi: 10.1016/S0006-3223(96)00094-7

131. Bashir Q, Acosta M. Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study. *Clin Lymphoma Myeloma Leuk* (2020) 20(11):768–73. doi: 10.1016/j.clml.2020.06.022

132. Pigneux A, Bene MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, et al. Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. *J Clin Oncol* (2018) 36(32):3203–10. doi: 10.1200/JCO.2018.78.7366

133. Megias-Vericat JE, Martinez-Cuadrón D, Sanz MA, Montesinos P. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. *Ann Hematol* (2018) 97 (7):1115–53. doi: 10.1007/s00277-018-3304-y

134. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. *Blood Adv* (2018) 2 (8):923–32. doi: 10.1182/bloodadvances.2018016121

135. Kico JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. *Blood* (2013) 121(9):1633–43. doi: 10.1182/blood-2012-09-459313

136. Miller AL, Geng C, Golovko G, Sharma M, Schwartz JR, Yan J, et al. Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells. *Cancer Cell Int* (2014) 14:35. doi: 10.1186/1475-2867-14-35

137. Valli D, Gruszka AM, Alcalay M. Has Drug Repurposing Fulfilled its Promise in Acute Myeloid Leukaemia? *J Clin Med* (2020) 9(6):1–30. doi: 10.3390/jcm9061892

**Conflict of Interest:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.